MedTrace Logo

IV Dexketoprofen vs Placebo in Migranie Attack

NCT02159547 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2015-07-23

Study results available
· View outcomes & findings →

Summary

H0 hypothesis: IV dexketoprofen is equivalent to placebo in ceasing migraine attack in emergency department.

H1 hypothesis: IV dexketoprofen is not equivalent (superior) to placebo in ceasing migraine attack in emergency department.

Conditions

Interventions

DRUG

Dexketoprofen

50 mg intravenous arveles in 50 ml saline in 5 minutes

OTHER

Normal Saline

50 ml normal saline

Sponsors & Collaborators

  • Akdeniz University

    lead OTHER

Principal Investigators

  • Faruk Gungor, Pyhsician · Antalya Training and Govermental Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159547 on ClinicalTrials.gov